

**Repeated administration of antidepressant drugs affects  
the levels of mRNA coding for D<sub>1</sub> and D<sub>2</sub> dopamine  
receptors in the rat brain**

**M. Dziedzicka-Wasylewska, R. Rogoż, V. Klimek, and J. Maj**

Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland

Accepted February 4, 1997

**Summary.** The present study examined the effects of acute and repeated administration of three antidepressant drugs (imipramine, citalopram and (+)-oxaprotiline) on the levels of mRNA coding for dopamine D<sub>1</sub> and D<sub>2</sub> receptors in the rat brain. Quantitative in situ hybridization with <sup>35</sup>S-labelled oligonucleotide probes has been utilised. The level of mRNA coding for dopamine D<sub>1</sub> receptor (D<sub>1</sub> mRNA) is decreased following repeated administration of imipramine, both in the nucleus accumbens and in the striatum. On the other hand, the repeated administration of citalopram, the selective inhibitor of serotonin reuptake, resulted in an increase in the level of D<sub>1</sub> mRNA in the striatum and in the core region of nucleus accumbens. A similar tendency, i.e.: an increase in the level of D<sub>1</sub> mRNA was observed after repeated administration of (+)-oxaprotiline, a selective inhibitor of noradrenaline reuptake. The level of mRNA coding for dopamine D<sub>2</sub> receptors (D<sub>2</sub> mRNA) was increased in all the brain regions studied, both after administration of imipramine and citalopram. (+)-Oxaprotiline did not produce any statistically significant changes in the level of D<sub>2</sub> mRNA.

The results obtained in this study indicate that the levels of mRNA coding for dopamine D<sub>1</sub> and D<sub>2</sub> receptors are regulated by the antidepressant drugs. The changes concerning the dopamine D<sub>2</sub> receptors are more consistent and fit in with the previously described binding and behavioral effects and seem to be important for the mechanism of action of antidepressant drugs.

**Keywords:** Antidepressant drugs, D<sub>1</sub> and D<sub>2</sub> mRNA, striatum, nucleus accumbens, rat.

### **Introduction**

Previous behavioural and neurochemical studies have shown that repeated antidepressant treatment influences the brain dopaminergic system. Repeated administration of antidepressant drugs increases locomotor hyperactivity induced by dopamine stimulants, possibly as a result of postsynaptic dopam-

inergic supersensitivity (Maj et al., 1984, 1987, 1989, 1991; Maj, 1986, 1990; Maj and Wędzony, 1985; Spyraiki and Fibiger, 1981; Martin-Iverson et al., 1983; Arnt et al., 1984; Prażnik and Kostowski, 1987; Serra et al., 1990). The hypothesis of supersensitivity of postsynaptic dopamine receptors, although well documented in behavioural studies, contrasts with the results of dopamine receptor binding studies, which suggest that after repeated treatment with antidepressant drugs dopamine D<sub>2</sub> receptor density as measured by [<sup>3</sup>H]-spiperone binding is unchanged, whereas that of dopamine D<sub>1</sub> receptors, measured by [<sup>3</sup>H]-SCH23390 binding, is decreased (Martin-Iverson et al., 1983; Klimek and Nielsen, 1987; De Montis et al., 1989). However, in further studies by Klimek and Maj (1989) it has been demonstrated that antidepressants given repeatedly increase the affinity of dopamine D<sub>2</sub> receptors for the agonist, evaluated by the displacement of [<sup>3</sup>H]-spiperone by quinpirole. We have recently shown that antidepressants (imipramine, amitriptyline, fluoxetine and mianserin), administered repeatedly, increase the affinity and the density of dopamine D<sub>2</sub> receptors, measured by the binding of the D<sub>2</sub> agonist [<sup>3</sup>H]-N-0437 (Maj et al., 1996). These findings are in line with the observation that repeated administration of antidepressants potentiates locomotor hyperactivity induced by dopamine agonists, among others by quinpirole (Maj, 1986, 1990).

Since clinical effects of antidepressant drugs are generally observed only after prolonged treatment, the biochemical changes underlying these effects may be secondary to alterations at the genomic level. Until recently, however, little was known about transcriptional and posttranscriptional factors regulated by chronic drug treatment, although long-term changes in neuronal synaptic function are known to be dependent upon selective regulation of gene expression (Karin, 1992). It has been recently shown that repeated treatment with lithium (Dziedzicka-Wasylewska and Wędzony, 1996) and also repeated but not acute electroconvulsive shock affects the level of mRNA coding for dopamine receptors in the rat nucleus accumbens (Smith et al., 1995).

The present study was therefore designed in order to obtain information on whether repeated administration of antidepressant drugs modifies the biosynthesis of postsynaptic dopamine D<sub>1</sub> and D<sub>2</sub> receptors. This aim was achieved by measuring the level of mRNA coding for dopamine D<sub>1</sub> and D<sub>2</sub> receptors in the rat striatum and the nucleus accumbens septi shell and core, using *in situ* hybridization.

Three antidepressant drugs with different pharmacological profiles have been used; imipramine – a noradrenaline and serotonin reuptake inhibitor, citalopram – a selective inhibitor of serotonin reuptake, and (+)-oxaprotiline – a selective noradrenaline reuptake inhibitor.

## Methods

### *Animals*

Male Wistar rats (180–220 g) were housed in groups of 10 on a natural day-night cycle at room temperature of 19–20°C with free access to food and tap water. The animals were

treated with antidepressant drugs at a dose of 10 mg/kg p.o., twice a day, at 8 a.m. and 5 p.m. for two weeks. Apart from the control groups, which received saline, there were groups of animals treated with a single dose of the appropriate drug. While not receiving the antidepressant drug, all rats were treated with saline p.o. All groups of animals, treated acutely or repeatedly with antidepressant drugs, were decapitated at the same time. This took place 2 or 72 h after the last dose. The brains of the rats were then rapidly removed and frozen on dry ice. The D<sub>1</sub> mRNA and D<sub>2</sub> mRNA measurements were carried out on the same groups of rats.

### *In situ hybridization*

Coronal sections (12 µm thick) were made on a cryostat through the nucleus accumbens septi and the striatum (caudate-putamen). The sections were thaw-mounted onto chrome alum pretreated slides and processed for in situ hybridization using the method described previously (Dziedzicka-Wasylewska and Rogoż, 1995). Briefly, a mixture of 48-mer synthetic deoxyoligonucleotides (New England Nuclear) complementary to bases 4–51, 766–813 and 901–948 of the rat D<sub>2</sub> dopamine receptor (Bunzow et al., 1988) and complementary to bases 13–60, 520–567 and 664–711 of the rat D<sub>1</sub> dopamine receptor (Zhou et al., 1990) were labelled using [<sup>35</sup>S]dATP (1,200 Ci/mmol, New England Nuclear). Tissue sections were thawed and fixed for 10 min in 4% paraformaldehyde in phosphate-buffered saline at 4°C. After three 5 min rinses in isotonic phosphate-buffered saline, sections were treated with 0.1 M triethanolamine (pH 8.0)/acetic anhydride (0.25%). The sections were then rinsed in 2 × SSC (300 mM NaCl/30 mM sodium citrate, pH 7.0) for 5 min, dehydrated through graded alcohols and allowed to air-dry. After this fixing and prehybridization, sections were treated with [<sup>35</sup>S]dATP-labelled probes. Probes were diluted in hybridization buffer [50% (vol/vol) formamide, 10% (wt/vol) dextran sulfate, 4 × SSC (pH 7.0), 1 × Denhardt's solution (= 0.02% polyvinylpyrrolidone/0.02% Ficoll/0.02% bovine serum albumine), yeast tRNA (0.25 mg/ml), sheared herring sperm DNA (0.2 mg/ml), 10 mM dithiothreitol] to result in a final concentration of 2 × 10<sup>6</sup> dpm/30 µl. All solutions were made up with autoclaved 0.1% diethylpyrocarbonate-treated water. Diluted probes (30 µl) were applied to sections, which were then covered with Parafilm. Hybridization occurred overnight in a humidified chamber at 39°C. Following hybridization, sections were washed in 1 × SSC for 10 min, then 4 times for 15 min each in 1 × SSC/50% formamide at 42°C, rinsed briefly in 1 × SSC and water at room temperature, then air-dried. Slides were then placed in X-ray cassettes, apposed to film (Amersham MP) for 20 days at –20°C. Different patterns of hybridization, found in the brain regions, fully agreed with the well known distribution of D<sub>1</sub> and D<sub>2</sub> receptors mRNAs (Mansour et al., 1991; Meador-Woodruff and Mansour, 1991) and provided support for the specificity of the probes under the present experimental conditions. The specificity of in situ hybridization was additionally assessed by pretreatment of some tissue sections with RNAase A (20 µg/ml) for 40 min at 30°C, which completely eliminated the hybridization signal with the cDNA probe.

Optical measurements were made from the autoradiograms corresponding to sections of the nucleus accumbens septi and the striatum, using an image analyzing system (Java: Jandel, Corte Madera CA, USA). The average optical density values were calculated after subtraction of the film background density. The mean optical density values were obtained by averaging out the measurements from autoradiograms of the 4–5 sections obtained from 5–6 animals per group.

### *Drugs*

The following drugs were used as antidepressants: imipramine HCl (Polfa, Poland); citalopram (Lundbeck, Denmark) and (+)-oxaprotiline (Ciba-Geigy, Germany).

### Statistics

The results were statistically assessed by a one-way analysis of variance (ANOVA) and inter-group differences were analyzed by Duncan's multiple range test.

### Results


Figure 1 presents examples of photomicrographs of brain sections hybridized with probes against dopamine D<sub>1</sub> receptor mRNA (A) and dopamine D<sub>2</sub> receptor mRNA (B). On Fig. 1C the diagrammatic representation of the areas used in optical density analysis of specific brain regions is shown.

The effects of antidepressant drugs on the level of mRNA coding for D<sub>1</sub> receptor (D<sub>1</sub> mRNA) are presented in Table 1. Repeated but not acute treatment with imipramine (2h and 72h after the last dose) resulted in a significant decrease in the level of D<sub>1</sub> mRNA in all the brain regions studied.

The D<sub>1</sub> mRNA level in the striatum started to increase already after a single dose of citalopram (72h after the drug administration) but the effect was not statistically significant. Citalopram given repeatedly resulted in a significant increase in the level of D<sub>1</sub> mRNA in the core region of the nucleus accumbens septi and in the striatum. On the other hand, we did not see any significant effect of repeated citalopram on the level of D<sub>1</sub> mRNA in the shell region of nucleus accumbens septi.

Repeated administration of (+)-oxaprotiline resulted in a slight increase of the level of D<sub>1</sub> mRNA in nucleus accumbens, at 72h after drug withdrawal.

The effects of antidepressant drugs on the level of mRNA coding for D<sub>2</sub> receptors (D<sub>2</sub> mRNA) are presented in Table 2. Already a single dose of imipramine (2h after administration) resulted in a slight increase in the level of mRNA D<sub>2</sub> both in the striatum and core region of the nucleus accumbens, but the results did not reach statistical significance. At 72h after a single dose



**Fig. 1.** Example photomicrographs of brain sections hybridised with probes against dopamine D<sub>1</sub> receptor mRNA (A) and dopamine D<sub>2</sub> receptor mRNA (B). C Shows diagrammatic representation of the areas used in optical density analysis of specific brain regions

**Table 1.** The effect of antidepressant drugs: imipramine (IMI), citalopram (CIT) and (+)-oxaprotiline (OXA) on the levels of mRNA [per cent of control level] coding for dopamine D<sub>1</sub> receptor in the striatum and nucleus accumbens septi (core and shell) of the rat

Treatment	Striatum	Nucleus accumbens	
		core	shell
<b>IMI</b> single, 2 h	104.5 ± 8.9	109.4 ± 4.6	112.5 ± 6.6
single, 72 h	114.5 ± 11.9	104.2 ± 7.8	92.3 ± 5.4
repeated, 2 h	72.6 ± 5.2*	76.8 ± 6.0*	72.3 ± 6.5*
repeated, 72 h	76.3 ± 6.6*	78.2 ± 6.4*	79.8 ± 7.5*
<b>CIT</b> single, 2 h	95.6 ± 2.9	102.7 ± 3.4	95.8 ± 7.3
single, 72 h	114.8 ± 4.9	105.2 ± 4.2	88.6 ± 4.2
repeated, 2 h	121.1 ± 7.5*	118.8 ± 6.8*	106.6 ± 5.8
repeated, 72 h	131.9 ± 3.3*	127.5 ± 5.6*	111.1 ± 7.0
<b>OXA</b> single, 2 h	96.2 ± 4.2	93.8 ± 6.4	89.9 ± 2.6
single, 72 h	105.9 ± 4.7	98.2 ± 3.7	90.3 ± 3.5
repeated, 2 h	105.6 ± 3.6	96.3 ± 4.1	108.0 ± 7.0
repeated, 72 h	111.5 ± 3.4	114.3 ± 4.2*	115.6 ± 3.2*

Imipramine (IMI), citalopram (CIT) and (+)-oxaprotiline (OXA) were administered in a single dose (single, 10 mg/kg p.o) or repeatedly (repeated, 10 mg/kg p.o. twice a day, for 14 days). Rats were killed 2 or 72 h after the last dose of the drug. The mean optical density values were obtained by averaging the measurements from autoradiograms of the 4–5 sections obtained from 5–6 animals per group and recalculated as percentage of the level of D<sub>1</sub> receptor mRNA in control animals. Control level of D<sub>1</sub> mRNA for striatum was 100% ± 4.5; for core region of nucleus accumbens was 100% ± 3.4; for shell region of nucleus accumbens was 100% ± 4.9. ANOVA followed by Duncan's test, \*p < 0.05 vs. the control level

of imipramine a significant increase in the level of D<sub>2</sub> mRNA was observed in all the brain regions examined. Repeated administration of imipramine caused an increase in the biosynthesis of D<sub>2</sub> receptor in all brain regions examined; the effect was statistically significant at both 2 and 72 h after the last dose of the drug.

Repeated (but not acute) administration of citalopram produced an increase of the level of D<sub>2</sub> mRNA in all the brain region studied. A similar tendency was observed already after a single dose of the drug, 72 h after the administration, but was not statistically significant.

(+)-Oxaprotiline did not produce any significant effects as far as the level of D<sub>2</sub> mRNA is concerned, neither after a single dose nor repeated administration, although generally the level of D<sub>2</sub> mRNA was lower than in the control group.

### Discussion

Most recently it has become clear that long-term changes in neuronal synaptic function are correlated with, and in some cases shown to be dependent on, the

**Table 2.** The effect of antidepressant drugs: imipramine (IMI), citalopram (CIT) and (+)-oxaprotiline (OXA) on the levels of mRNA [per cent of control level] coding for dopamine D<sub>2</sub> receptors in the striatum and nucleus accumbens septi (core and shell) of the rat

Treatment	Striatum	Nucleus accumbens	
		core	shell
<b>IMI</b> single, 2h	113.0 ± 5.9	114.9 ± 8.0	108.6 ± 3.6
single, 72h	139.6 ± 8.2*	138.2 ± 6.8*	134.8 ± 5.2*
repeated, 2h	129.3 ± 5.6*	132.8 ± 7.4*	136.2 ± 6.3*
repeated, 72h	136.4 ± 3.8*	136.2 ± 5.2*	140.3 ± 6.4*
<b>CIT</b> single, 2h	109.2 ± 4.3	106.3 ± 5.6	110.5 ± 4.1
single, 72h	115.5 ± 7.0	113.2 ± 8.2	116.0 ± 4.8
repeated, 2h	122.0 ± 3.2*	119.7 ± 6.4*	126.5 ± 6.3*
repeated, 72h	129.6 ± 4.2*	122.5 ± 3.5*	128.6 ± 7.2*
<b>OXA</b> single, 2h	92.8 ± 1.8	96.3 ± 2.3	92.0 ± 3.5
single, 72h	92.0 ± 2.0	93.3 ± 2.4	95.2 ± 7.3
repeated, 2h	95.6 ± 3.6	94.5 ± 3.2	88.7 ± 6.1
repeated, 72h	96.7 ± 5.0	98.4 ± 2.4	87.9 ± 4.5

Imipramine (IMI), citalopram (CIT) and (+)-oxaprotiline (OXA) were administered in a single dose (single, 10mg/kg p.o) or repeatedly (repeated, 10mg/kg p.o. twice a day, for 14 days). Rats were killed 2 or 72h after the last dose of the drug. The mean optical density values were obtained by averaging the measurements from autoradiograms of the 4–5 sections obtained from 5–6 animals per group and recalculated as percentage of the level of D<sub>2</sub> receptor mRNA in control animals. Control level of D<sub>2</sub> mRNA for striatum was 100% ± 5.2; for core region of nucleus accumbens was 100% ± 4.5; for shell region of nucleus accumbens was 100% ± 4.8. ANOVA followed by Duncan's test, \*p < 0.05 vs. the control level

induction of new programs of gene expression (Karin, 1992; Sheng and Greenberg, 1990). Recent successful cloning of the genes coding for the dopamine receptors (Bunzow et al., 1988; Civelli et al., 1991; Zhou et al., 1990) offered the opportunity to study the modulation of the dopaminergic system at the level of receptor gene expression. It has also become apparent that receptor activity may be coupled to receptor biosynthesis, thus maintaining dopaminergic homeostasis in the brain. It has already been reported that dopamine receptor mRNA synthesis is affected by dopamine agonists, neuroleptics and 6-hydroxydopamine (Angulo et al., 1991; Chen et al., 1991, 1993; Coirini et al., 1990; Gerfen et al., 1990; Graham et al., 1990; Jongen-Rêlo et al., 1994; Le Moine et al., 1990; Savasta et al., 1988). Regulation of receptor expression by agonists has been recently described for other receptors (Hadcock and Malbon, 1991). The present study provides data indicating that antidepressant drugs, whose mechanism of action is not directly linked to dopaminergic neurotransmission, also profoundly influence the levels of mRNA coding for dopamine D<sub>1</sub> and D<sub>2</sub> receptors in the rat brain.

The results presented in this paper remain in line with our previous behavioural and receptor binding findings (see: Introduction), in-

dicating that antidepressants administered repeatedly affect the dopaminergic system.

The level of mRNA coding for dopamine  $D_1$  receptors is decreased following repeated administration of imipramine, both in the nucleus accumbens and in the striatum. On the other hand, repeated administration of citalopram, the selective inhibitor of serotonin reuptake, resulted in an increase in the level of mRNA coding for dopamine  $D_1$  receptor in the striatum and in the core region of nucleus accumbens. A similar tendency, i.e. an increase in the level of mRNA coding for dopamine  $D_1$  receptors was observed after the repeated administration of (+)-oxaprotiline. The results reached statistical significance only in the nucleus accumbens, after 72h of repeated administration of the drug. Since in the previous studies a decrease in the binding sites of [ $^3$ H]SCH23390 was observed following the administration of antidepressant drugs (Klimek and Nielsen, 1987) – the results obtained at the level of mRNA coding for dopamine  $D_1$  receptors following imipramine administration seem to match well with the binding studies. However, other antidepressants used in the present study, did not produce a similar effect. As it has been already discussed by others (Civelli et al., 1991; Jongen-Rêlo et al., 1994; Mansour et al., 1990), the precise relationship between receptor synthesis and the availability of the functional receptors in the neuronal membrane is not known. A complex series of events occurs, including post-transcriptional, translational and post-translational processes, the subsequent incorporation of the receptor protein into cell membrane, coupling through G proteins with the effector systems, and eventually degradation of the receptors. The precise relationships between the alterations in gene transcription, mRNA stability, translational processes and dopamine receptor binding remain to be clarified. For example, Jongen-Rêlo et al. (1994) found that following a 6-hydroxydopamine lesion,  $D_1$  mRNA levels were decreased in the core and shell regions of the nucleus accumbens and in the striatum, whereas, in contrast,  $D_1$  receptor density was increased in these three areas.

It may also well be that the changes at the level of dopamine  $D_1$  receptors are less important for the mechanism of action of antidepressant drugs than are the changes concerning the dopamine  $D_2$  receptors, which seem more consistent. It has been postulated (Serra et al., 1990) that chronic treatment with antidepressant drugs potentiates behavioral responses mediated by the stimulation of postsynaptic  $D_2$  receptors in the mesolimbic system and suggested that this behavioral supersensitivity is due to the enhanced neurotransmission at the  $D_1$  receptor level. One may consider the down-regulation of the  $D_1$  receptors as an adaptive change to the overstimulation of this receptor. Since not all antidepressant drugs are able to induce similar changes in the synaptic dopamine concentration at the same time, which in turn may influence the density of dopamine  $D_1$  receptors, a variation in the effects is observed in the present study at the level of mRNA coding for  $D_1$  receptor.

The level of mRNA coding for dopamine  $D_2$  receptors is increased following the administration of imipramine and citalopram. The effect started to be statistically significant already 72h after a single dose of imipramine – what

may indicate that even a single dose of the drug is sufficient to trigger changes in the transcription of the gene encoding dopamine D<sub>2</sub> receptors, what may later result in the increase in the density of functionally mature D<sub>2</sub> receptors in the cell membrane. From our recently published binding studies (Maj et al., 1996) we know that, using an agonist for dopamine D<sub>2</sub> receptors ([<sup>3</sup>H] N-0437) as a radioligand, we observed an increase in the density of D<sub>2</sub> receptors following the administration of imipramine and other antidepressant drugs. These results correspond with the previous behavioral studies showing an enhanced response to dopamine D<sub>2</sub> receptor stimulation following antidepressant drugs administration.

Although not all points can be fully clarified at present, it seems more apparent that alterations in the expression of genes coding for neurotransmitter receptors is the very level where one should search for the mechanism of action of drugs being therapeutically effective only after a prolonged administration.

### Acknowledgements

The authors are grateful to Ciba-Geigy (Frankfurt a/M) for their kind gift of (+)-oxaprotiline, to Lundbeck for citalopram and to Polfa for imipramine.

The skillful technical assistance of Ms.B. Adamczyk is highly appreciated.

This work was supported by a Grant KBN No 6 P207 082 06 from the Committee for Scientific Research, Poland.

### References

- Angulo JA, Coirini H, Ledoux M, Schumacher M (1991) Regulation by dopaminergic neurotransmission of dopamine D<sub>2</sub> mRNA and receptor levels in the striatum and nucleus accumbens of the rat. *Mol Brain Res* 11: 161–166
- Arnt J, Hyttel J, Fredrickson Overø K (1984) Prolonged treatment with the specific 5-HT-uptake inhibitor citalopram: effect on dopaminergic and serotonergic functions. *Pol J Pharmacol Pharm* 36: 221–230
- Bunzow JR, Van Tol HHM, Grandy DK, Albert P, Salon J, Christie M, Machida CA, Neve KA, Civelli O (1988) Cloning and expression of a rat D<sub>2</sub> dopamine receptor cDNA. *Nature* 336: 783–787
- Chen J, Qin ZH, Szele F, Bai G, Weiss B (1991) Neuronal localization and modulation of the D<sub>2</sub> dopamine receptor mRNA in brain of normal mice and mice lesioned with 6-hydroxydopamine. *Neuropharmacology* 30: 927–941
- Chen JF, Aloyo VJ, Weiss B (1993) Continuous treatment with the D<sub>2</sub> dopamine receptor agonist quinpirole decreases D<sub>2</sub> dopamine receptors, D<sub>2</sub> dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum. *Neuroscience* 54: 669–680
- Civelli O, Bunzow JR, Grandy DK, Zhou Q-Y, Van Tol HHM (1991) Molecular biology of the dopamine receptors. *Eur J Pharmacol* 207: 277–286
- Coirini H, Schumacher M, Angulo JA, McEwen BS (1990) Increase in striatal dopamine D<sub>2</sub> receptor mRNA after lesions or haloperidol treatment. *Eur J Pharmacol* 186: 369–371
- De Montis GM, Devoto P, Gessa GL, Meloni D, Porcella A, Saba P, Serra G, Tagliamonte A (1989) Chronic imipramine reduces [<sup>3</sup>H]SCH 23390 binding and DA-sensitive adenylate cyclase in the limbic system. *Eur J Pharmacol* 167: 299–303
- Dziedzicka-Wasylewska M, Rogoż R (1995) The effect of prolonged treatment with imipramine and electroconvulsive shock on the levels of endogenous enkephalins in



- the nucleus accumbens and the ventral tegmentum of the rat. *J Neural Transm [Gen Sect]* 102: 221–228
- Dziedzicka-Wasylewska M, Wędzony K (1996) The effect of prolonged administration of lithium on the level of dopamine D<sub>2</sub> receptor mRNA in the rat striatum and nucleus accumbens. *Acta Neurobiol Exp* 56: 29–34
- Gerfen CR, Engber TM, Mahan LC, Susel Z, Chase TN, Monsma FJ Jr, Sibley DR (1990) D<sub>1</sub> and D<sub>2</sub> dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. *Science* 250: 1429–1432
- Graham WC, Crossman AR, Woodruff GN (1990) Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D<sub>2</sub> but not D<sub>1</sub> receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat. *Brain Res* 514: 93–102
- Hadcock JR, Malbon CC (1991) Regulation of receptor expression by agonists: transcriptional and post-transcriptional controls. *Trends Neurosci* 14: 242–247
- Jongen-Rêlo AL, Docter GJ, Jonker AJ, Vreugdenhil E, Groenewegen HJ, Voorn P (1994) Differential effects of dopamine depletion on the binding and mRNA levels of dopamine receptors in the shell and core of the rat nucleus accumbens. *Mol Brain Res* 25: 333–343
- Karin M (1992) Signal transduction from cell surface to nucleus in development and disease. *FASEB J* 6: 2581–2590
- Klimek V, Nielsen M (1987) Chronic treatment with antidepressants decreases the number of <sup>3</sup>H-SCH 23390 binding sites in the rat striatum and the limbic system. *Eur J Pharmacol* 139: 163–169
- Klimek V, Maj J (1989) Repeated administration of antidepressants enhances agonist affinity for mesolimbic D<sub>2</sub> receptors. *J Pharm Pharmacol* 41: 555–558
- Le Moine C, Normand E, Guitteny AF, Fouque B, Teoule R, Bloch B (1990) Dopamine receptor gene expression by enkephalin neurons in rat forebrain. *Proc Natl Acad Sci USA* 87: 230–234
- Maj J (1986) Repeated treatment with antidepressant drugs: responses mediated by brain dopamine receptors. In: Hippus H, Klerman GL, Matussek N (eds) *New results in depression research*. Springer, Berlin Heidelberg New York Tokyo, pp 90–98
- Maj J (1990) Behavioural effects of antidepressant drugs given repeatedly on the dopaminergic system. In: Gessa GL, Serra G (eds) *Advances in the biosciences* 77. Pergamon Press, Oxford, pp 139–1
- Maj J, Wędzony K (1985) Repeated treatment with imipramine or amitriptyline increases the locomotor response of rats to (+)-amphetamine given into the nucleus accumbens. *J Pharm Pharmacol* 37: 362–364
- Maj J, Rogóż Z, Skuza G, Sowińska H (1984) Repeated treatment with antidepressant drugs potentiates the locomotor response to (+)-amphetamine. *J Pharm Pharmacol* 36: 127–130
- Maj J, Wędzony K, Klimek V (1987) Desipramine given repeatedly enhances behavioural effects of dopamine and d-amphetamine injected into the nucleus accumbens. *Eur J Pharmacol* 140: 179–185
- Maj J, Papp M, Skuza G, Bigajska K, Zazula M (1989) The influence of repeated treatment with imipramine, (+)- and (–)-oxaprotyline on behavioural effects of dopamine D-1 and D-2 agonists. *J Neural Transm* 76: 29–38
- Maj J, Klimek V, Rogóż Z, Skuza G, Sowińska H (1991) The effect of (+)- and (–)-oxaprotyline administered repeatedly on the dopamine system. *J Neural Transm [Gen Sect]* 86: 11–23
- Maj J, Dziedzicka-Wasylewska M, Rogóż R, Rogóż Z, Skuza G (1996) Antidepressant drugs given repeatedly change the binding of the dopamine D<sub>2</sub> agonist, [<sup>3</sup>H]-N-0437, to D<sub>2</sub> receptors in the rat brain. *Eur J Pharmacol* 304: 49–54
- Mansour A, Meador-Woodruff JH, Bunzow JR, Civelli O, Akil H, Watson SJ (1990) Localization of dopamine D<sub>2</sub> receptor mRNA and D<sub>1</sub> and D<sub>2</sub> receptor binding in

- the rat brain and pituitary: an in situ hybridization-receptor autoradiographic analysis. *J Neurosci* 10: 2587–2600
- Mansour A, Meador-Woodruff JH, Zhou Q-Y, Civelli O, Akil H, Watson SJ (1991) A comparison of D<sub>1</sub> receptor binding and mRNA in rat brain using receptor autoradiographic analysis and in situ hybridization techniques. *Neuroscience* 45: 359–371
- Martin-Iverson MT, Leclere J-F, Fibiger HC (1983) Cholinergic-dopaminergic interactions and the mechanisms of action of antidepressants. *Eur J Pharmacol* 94: 193–201
- Meador-Woodruff JH, Mansour A (1991) Expression of the dopamine D<sub>2</sub> receptor gene in the brain. *Biol Psychiatry* 30: 985–1007
- Prażnik A, Kostowski W (1987) The effects of antidepressants and electroconvulsive shocks on the functioning of the mesolimbic dopaminergic system: a behavioral study. *Eur J Pharmacol* 135: 389–396
- Savasta M, Dubois A, Benavides J, Scatton B (1988) Different plasticity changes in D<sub>1</sub> and D<sub>2</sub> receptors in rat striatal subregions following impairment of dopaminergic transmission. *Neurosci Lett* 85: 119–124
- Serra G, Collu M, D'Aquila PS, De Montis GM, Gessa GL (1990) Possible role of dopamine D<sub>1</sub> receptor in the behavioural supersensitivity to dopamine agonists induced by chronic treatment with antidepressants. *Brain Res* 527: 234–243
- Sheng M, Greenberg ME (1990) The regulation and function of c-fos and other immediate early genes in the nervous system. *Neuron* 4: 477–485
- Smith S, Linderfros N, Hurd Y, Sharp T (1995) Electroconvulsive shock increases dopamine D<sub>1</sub> and D<sub>2</sub> receptor mRNA in the nucleus accumbens of the rat. *Psychopharmacology* 120: 333–340
- Spyraki Ch, Fibiger HC (1981) Behavioral evidence for supersensitivity of postsynaptic dopamine receptors in the mesolimbic system after chronic administration of desipramine. *Eur J Pharmacol* 74: 195–206
- Zhou QY, Grandy DK, Thambi L, Kushner JA, Van Tol HHM, Cone R, Pribnow D, Salon J, Bunzow JR, Civelli O (1990) Cloning and expression of human and rat D<sub>1</sub> dopamine receptors. *Nature* 347: 76–80

Authors' address: Dr. M. Dziedzicka-Wasylewska, Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, PL-31343 Kraków, Poland.

Received June 27, 1996